Press Release Communiqué de presse - May 26, 2020 26 May, 2020

SERNOVA ANNOUNCES CHANGE OF LOCATION OF ANNUAL MEETING OF SHAREHOLDERS

May 26, 2020 - For Immediate Release

LONDON, ONTARIO – May 26, 2020 – Sernova Corp. (TSX-V:SVA) (OTCQB:SEOVF)(FSE:PSH) (the "Corporation" or "Sernova") announces that the Board of Directors of the Corporation have considered current COVID-19 public health restrictions and determined it to be in the best interests of the Corporation and its shareholders to change the location of the Corporation's annual meeting of shareholders ("AGM") to the offices of Sernova at 700 Collip Circle, Suite 114, London, Ontario N6G 4X8. The AGM will be held on Friday, May 29, 2020, at 12:00 p.m. (Eastern Time). Shareholders are reminded to submit their votes by proxy before the proxy deadline of 12:00 p.m. (Eastern Time) on Wednesday, May 27, 2020. Shareholders may choose to attend the meeting by teleconference but will not be able to vote via teleconference. All other matters of the AGM remain the same as published in the AGM proxy materials mailed to the shareholders and posted at www.sedar.com.

The conference call details for shareholders to call into the AGM are set out below.

US Toll-Free: + 1-877-366-0711 Canada Toll-Free: + 1-866-627-1651 Int’l Toll-Free: + 1-302-709-8446 The conference participant passcode is 109 985 50.

Following the AGM, Sernova will hold a CEO conference call at 1:00 p.m. (Eastern Time) for its shareholders and investors. The CEO conference call details are set out below.

https://zoom.us/j/96039720141?pwd=TThubnVBSE1kb2hudzQ1TVZ0OEovUT09 Meeting ID: 960 3972 0141 Password: Sernova

A recording will be available following the meeting at www.sernova.com/investor/agm

About Sernova's Cell Pouch System The Cell Pouch™, as part of the Cell Pouch System, is a novel, proprietary, scalable, implantable macroencapsulation device solution designed for the long-term survival and function of therapeutic cells. The device upon implantation is designed to incorporate with tissue, forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells, which then release proteins and hormones as required to treat disease. The Cell Pouch, along with therapeutic cells, has been shown to provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for insulin-producing cells in humans.

About Sernova Corp. Sernova Corp. is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells (i.e., human donor cells, corrected human cells and stem-cell-derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin- dependent diabetes, blood disorders including hemophilia and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Dominic Gray Sernova Corp Tel: (519) 858-5126 dominic.gray@sernova.com

Press Release Communiqué de presse - May 19, 2020 19 May, 2020

Sernova Highlights Achievements of the HemAcure Hemophilia Cell Therapy Program Presented at ASGCT

Sernova’s Cell Pouch transplanted with Factor VIII corrected human cells shows robust functional blood clotting improvement demonstrating a novel first-in-class ex vivo gene therapy cell-based approach for the treatment of hemophilia A

May 19, 2020 9:00 a.m. EDT LONDON, ONTARIO – May 19, 2020 – Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE:PSH), a clinical-stage regenerative medicine therapeutics company, highlights positive results associated with the development of a novel, safe cell therapy approach, including our proprietary Cell Pouch™, for the treatment of hemophilia A as presented on May 15, 2020, by the Horizon 2020 HemAcure Consortium at the American Society of Gene and Cell Therapy’s 23rd Annual Meeting (ASGCT).

The aim of the HemAcure three-year project was to develop a permanent safe therapeutic solution for those living with hemophilia A in the form of a novel ex vivo gene therapy, cell-based approach within Sernova’s proprietary Cell Pouch. This combination therapy strives to permanently replace missing clotting human factor VIII (FVIII) in the patient’s own Blood Outgrowth Endothelial Cells (BOECs) transplanted into the Cell Pouch. These corrected cells are to function to release FVIII into the bloodstream restoring the ability for blood clotting to occur during periods of bleeding.

The following are highlights of the results presented • BOECs were safely isolated and grown from a small sample of circulating peripheral blood of volunteer Hemophilia A patients unable to express the required FVIII for clotting. • To regain the function of the BOECs ability to produce clotting FVIII, techniques were successful in safely inserting the gene responsible for the correction and production of human FVIII into the patient’s BOECs, and these corrected cells were safely multiplied to increase their number. • Tests were conducted to ensure the safety, and the newly corrected BOECs produced enough human FVIII both in the laboratory and in an initial preclinical animal model deficient of FVIII. FVIII blood levels reached up to 10%, a therapeutically relevant level of FVIII. • To further test cell dose-response, in the preclinical model of hemophilia A, animals originally unable to clot their blood were implanted with a small vascularized Cell Pouch and transplanted with two different doses of human BOECs corrected for the ability to produce human FVIII. • To assess the safety of the combined product, the Cell Pouch and corrected human FVIII BOECs derived from the volunteer participants with hemophilia A were examined using histological analyses. Importantly, histology showed healthy tissue represented by the presence of stromal growth and new blood vessel formation within the Cell Pouch. • Further, histological investigation of the transplanted Cell Pouch sections demonstrated long-term survival of human FVIII BOECs present within the vascularized Cell Pouch achieved through co-staining for blood vessels (von Willebrand Factor stain) and the presence of the patients corrected human cells (HLA-ABC stain). • In both experimental doses, human FVIII was detected in circulating peripheral blood up to 16 weeks following transplantation, with more human FVIII present in peripheral blood using the higher dose of corrected BOECs. • Data further confirmed functional clotting improvement in the blood at the four months time point where FVIII BOECs transplanted into the hemophilia A mouse model restored the animals FVIII activity at a therapeutic level in the Cell Pouch.

In summary, these results demonstrate the success of the HemAcure Consortium team in developing a novel approach for the treatment of hemophilia A using an ex vivo gene therapy, cell-based technology that could lead to improved efficacy and quality of life of people suffering from hemophilia A.

“These promising results of the HemAcure consortium are paving the way for future human clinical testing in hemophilia A patients using Sernova’s technologies transplanted with corrected FVIII cells developed by this prestigious international team. This initiative continues to support the value of collaborative efforts involving Sernova’s regenerative medicine technologies in both diabetes and now rare diseases such as hemophilia A,” said Dr. Philip Toleikis, President and CEO of Sernova Corp.

ABOUT HEMACURE The overall objective of the HemAcure Project is to develop and refine the tools and technologies for a novel ex vivo prepared cell-based therapy to treat the bleeding disease, hemophilia A (caused by a genetic deficiency in clotting factor VIII) that should ultimately lead to improved quality of life of the patients. The European Union’s Horizon 2020 Research and Innovation program awarded approximately €5.5 million (~CDN$8.5 million) to support the project. International consortium members include the University Hospital Würzburg (Coordinating Institute), Germany, IMS - Integrierte Management, Heppenheim, Germany; Università del Piemonte Orientale “Amedeo Avogadro,” Novara, Italy; Loughborough University, Loughborough, United Kingdom; ARTTIC International Management Services, Munich, Germany; and Sernova Corp., London, Ontario, Canada. For more information, visit www.hemacure.eu

ABOUT SERNOVA’S CELL POUCH SYSTEM The Cell Pouch, as part of the Cell Pouch System, is a novel, proprietary, scalable, implantable macro- encapsulation device solution designed for the long-term survival and function of therapeutic cells. The device upon implantation is designed to incorporate with tissue, forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells, which then release proteins and hormones as required to treat disease. The Cell Pouch, along with therapeutic cells, has been shown to provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for insulin-producing cells in humans.

ABOUT SERNOVA CORP. Sernova Corp. is developing regenerative medicine cell therapy therapeutic technologies using a medical device and immune protected therapeutic cells (i.e., human donor cells, corrected human cells and stem cell-derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin- dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com.

FOR FURTHER INFORMATION, PLEASE CONTACT: Dominic Gray Sernova Corp. Tel: (519) 858-5126 dominic.gray@sernova.com www.sernova.com

FORWARD-LOOKING INFORMATION This release contains statements that to the extent they are not recitations of historical facts, may constitute “forward-looking statements” that involve various risks, uncertainties, and assumptions, including, without limitation, statements regarding the prospects, plans, and objectives of the company. Wherever possible, but not always, words such as "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential for" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur are used to identify forward-looking statements. These statements reflect management’s beliefs with respect to future events and are based on information currently available to management on the date such statements were made. Many factors could cause Sernova’s actual results, performances, or achievements, including those pertaining to the development of a therapeutic product to treat hemophilia A to not be as anticipated, estimated or intended or to differ materially from those expressed or implied by the forward- looking statements contained in this news release. Such factors could include, but are not limited to, the company’s ability to secure additional financing and licensing arrangements on reasonable terms, or at all; ability to conduct all required preclinical and clinical studies for the company’s Cell Pouch System and/or related technologies, including the timing and results of those trials; ability to obtain all necessary regulatory approvals, or on a timely basis; ability to in-license additional complementary technologies; ability to execute its business strategy and successfully compete in the market; and the inherent risks associated with the development of biotechnology combination products generally. Many of the factors are beyond our control, including those caused by, related to, or impacted by the novel coronavirus pandemic. Investors should consult the company’s quarterly and annual filings available on www.sedar.com for additional information on risks and uncertainties relating to the forward-looking statements. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Press Release Communiqué de presse - May 12, 2020 12 May, 2020

Sernova Announces Presentation of HemAcure Hemophilia Program Results at 23rd Annual Meeting of the American Society of Gene and Cell Therapy

May 12, 2020 9:00 a.m. EDT

LONDON, ONTARIO – May 12, 2020 – Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE:PSH), a clinical-stage regenerative medicine therapeutics company, is pleased to announce that the Horizon 2020 HemAcure Consortium will present scientific results of the consortium’s research in an abstract entitled Combined Gene and Cell Therapy for the Treatment of Hemophilia A within an Implantable Therapeutic Device in an oral presentation during the ASGCT 23rd Annual Meeting, which is being held in virtual format May 12-15, 2020. The abstract will be presented on May 15 at 11:30 am EDT.

The abstract being presented describes scientific results of the HemAcure Consortium’s research to develop a novel ex vivo cell-based therapy for the treatment of Hemophilia A using Sernova’s Cell Pouch™ and paves the way for future clinical testing. Abstract 1359 can be viewed at: https://www.asgct.org/global/documents/abstract-pdf-final-4-30?_zs=S2i4b&_zl=U9052

“The Horizon 2020 grant program enabled international experts and innovators in their field, including the Sernova team, to form the HemAcure Consortium to advance the next-generation cell-based regenerative medicine therapy aimed to improve the quality of life for people with hemophilia A. We are excited for members of the HemAcure team to present additional scientific updates at the ASGCT Annual Meeting that further supports Sernova’s technologies and their potential in a novel future therapeutic treatment for hemophilia A,” said Dr. Philip Toleikis, President and CEO of Sernova Corp.

ABOUT HEMACURE The overall objective of the HemAcure project is to develop and refine the tools and technologies for a novel ex vivo prepared cell-based therapy to treat the bleeding disease, hemophilia A (caused by a genetic deficiency in clotting factor VIII (FVIII)) that should ultimately lead to improved quality of life of the patients. The European Union’s Horizon 2020 research and innovation program has awarded approximately €5.5 million (CDN$8.5) to support the project. International consortium members include the University Hospital Würzburg (Coordinating Institute), Germany, IMS - Integrierte Management, Heppenheim, Germany, Università del Piemonte Orientale “Amedeo Avogadro,” Novara, Italy, Loughborough University, Loughborough, United Kingdom, ARTTIC International Management Services, Munich, Germany and Sernova Corp., London, Ontario, Canada. For more information, visit www.hemacure.eu

ABOUT SERNOVA’S CELL POUCH SYSTEM The Cell Pouch, as part of the Cell Pouch System, is a novel, proprietary, scalable, implantable macro- encapsulation device solution designed for the long-term survival and function of therapeutic cells. The device upon implantation is designed to incorporate with tissue, forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells, which then release proteins and hormones as required to treat disease. The Cell Pouch, along with therapeutic cells, has been shown to provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for insulin-producing cells in humans.

ABOUT SERNOVA CORP. Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells ( i.e., human donor cells, corrected human cells and stem cell-derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com.

FOR FURTHER INFORMATION, PLEASE CONTACT: Dominic Gray Sernova Corp. Tel: (519) 858-5126 dominic.gray@sernova.com www.sernova.com

FORWARD-LOOKING INFORMATION This release contains statements that to the extent they are not recitations of historical facts, may constitute “forward-looking statements” that involve various risks, uncertainties, and assumptions, including, without limitation, statements regarding the prospects, plans, and objectives of the company. Wherever possible, but not always, words such as "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential for" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur are used to identify forward-looking statements. These statements reflect management’s beliefs with respect to future events and are based on information currently available to management on the date such statements were made. Many factors could cause Sernova’s actual results, performances or achievements to not be as anticipated, estimated or intended or to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors could include, but are not limited to, the company’s ability to secure additional financing and licensing arrangements on reasonable terms, or at all; ability to conduct all required preclinical and clinical studies for the company’s Cell Pouch System and/or related technologies, including the timing and results of those trials; ability to obtain all necessary regulatory approvals, or on a timely basis; ability to in-license additional complementary technologies; ability to execute its business strategy and successfully compete in the market; and the inherent risks associated with the development of biotechnology combination products generally. Many of the factors are beyond our control, including those caused by, related to, or impacted by the novel coronavirus pandemic. Investors should consult the company’s quarterly and annual filings available on www.sedar.com for additional information on risks and uncertainties relating to the forward-looking statements. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Press Release Communiqué de presse - April 27, 2020 27 April, 2020

Sernova Advances Annual General Meeting and CEO Teleconference to Friday May 29

April 27, 2020 9:00 a.m. EDT

LONDON, ONTARIO – April 27, 2020 – Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE:PSH) announced today, with its continued COVID-19 vigilance, social gathering size restrictions in effect imposed by public health authorities and the now anticipated near term relaxation of certain COVID-19 public health-related restrictions, the Annual General Meeting (AGM) and CEO teleconference call originally scheduled for Thursday, April 30, 2020, has been adjourned to May 29, 2020, at 9:00 a.m. and 10:00 a.m. (Pacific Time), respectively. All other aspects of the AGM remain the same as published in the AGM materials, filed on www.sedar.com and available on www.sernova.com/investor/agm.

“Sernova has historically encouraged its shareholders to attend our AGM in person. Given the current restrictions imposed by the Canadian and provincial governments to reduce the spread of COVID-19, including restrictions on social gatherings, and travel, and feedback from our shareholders desiring to attend, we have decided to adjourn the AGM for 30 days to ensure the safety of everyone who may want to attend the meeting and to continue doing our part to help “flatten the curve.” We continue to monitor the COVID-19 situation actively and update our company policies accordingly to make proactive adjustments, and we appreciate our shareholders’ support while we safely continue our operations,” stated Dr. Philip Toleikis, President and CEO of Sernova.

The conference call details for the Annual Meeting of Shareholders are set out below.

US Toll-Free: + 1-877-366-0711

Canada Toll-Free: + 1-866-627-1651

Int’l Toll-Free: + 1-302-709-8446

The conference participant passcode is 109 985 50. Following the conference call, a recording will be available at www.sernova.com/investor/agm

ABOUT SERNOVA’S CELL POUCH SYSTEM

The Cell Pouch™, as part of the Cell Pouch System, is a novel, proprietary, scalable, implantable macro- encapsulation device solution designed for the long-term survival and function of therapeutic cells. The device upon implantation is designed to incorporate with tissue, forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells, which then release proteins and hormones as required to treat disease. The Cell Pouch, along with therapeutic cells, has been shown to provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for insulin-producing cells in humans.

ABOUT SERNOVA CORP.

Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells (i.e., human donor cells, corrected human cells and stem-cell-derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin- dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com

FOR FURTHER INFORMATION, PLEASE CONTACT:

Dominic Gray Sernova Corp Tel: (519) 858-5126 dominic.gray@sernova.com www.sernova.com

FORWARD-LOOKING INFORMATION This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of Sernova’s management on the date such statements were made, which include our beliefs about the effect on company operations of the COVID-19 virus and conduct and outcome of discussions, clinical programs, and our clinical trials. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Press Release Communiqué de presse - April 21, 2020 21 April, 2020

Important COVID-19 Safety Measures for Sernova s 2020 Annual Meeting of Shareholders

April 21, 2020 9:00 a.m. EDT

LONDON, ONTARIO – April 21, 2020 – Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE:PSH), a clinical-stage regenerative medicine therapeutics company, announced today that it is implementing safety measures for its upcoming Annual Meeting of Shareholders (“AGM”) to be held in Vancouver, BC on April 30, 2020, in response to public health authority guidelines issued concerning the COVID-19 pandemic.

Public health authorities across Canada continue to advise that both in-person contact and the congregation of groups be minimized in order to mitigate the risk of COVID-19 exposure or infection. Accordingly, shareholders are requested and strongly encouraged to vote electronically or by proxy on the matters before the meeting rather than attending the AGM in person. Voting instructions have been mailed to shareholders, and AGM related documents are accessible at www.sernova.com/investor/agm/. Immediately following the formal AGM, Sernova will host a conference call, and Dr. Philip Toleikis, President and CEO, will provide an update on Sernova’s activities and respond to shareholder questions. Questions may be submitted to info@sernova.com prior to the call.

“The health and well-being of our shareholders, employees, collaborators, and communities, as well as preventing the spread of the COVID-19 virus is of utmost importance. We have been closely monitoring the COVID-19 situation and updating our company policies accordingly to make proactive adjustments and continue operations while doing our part to help ‘flatten the curve.’ We appreciate our shareholders’ cooperation and understanding as the world navigates through these unprecedented times,” said Dr. Philip Toleikis, President and CEO of Sernova Corp.

The conference call details for the Annual Meeting of Shareholders are set out below.

US Toll-Free: + 1-877-366-0711

Canada Toll-Free: + 1-866-627-1651

Int’l Toll-Free: + 1-302-709-8446

The conference participant passcode is 109 985 50. Following the conference call, a recording will be available at www.sernova.com/investor/agm

ABOUT SERNOVA’S CELL POUCH SYSTEM The Cell Pouch, as part of the Cell Pouch System, is a novel, proprietary, scalable, implantable macro- encapsulation device solution designed for the long-term survival and function of therapeutic cells. The device upon implantation is designed to incorporate with tissue, forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells, which then release proteins and hormones as required to treat disease. The Cell Pouch, along with therapeutic cells, has been shown to provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for insulin-producing cells in humans.

ABOUT SERNOVA CORP. Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells (i.e., human donor cells, corrected human cells and stem-cell-derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com

FOR FURTHER INFORMATION, PLEASE CONTACT: Dominic Gray Sernova Corp Tel: (519) 858-5126 dominic.gray@sernova.com www.sernova.com

FORWARD-LOOKING INFORMATION This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of Sernova’s management on the date such statements were made, which include our beliefs about the effect on company operations of the COVID-19 virus and conduct and outcome of discussions, clinical programs, and our clinical trials. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Press Release Communiqué de presse - March 24, 2020 24 March, 2020

Sernova Provides Corporate Update and Outlook for 2020

March 24, 2020 9:00 a.m. EDT

LONDON, ONTARIO – March 24, 2020 – Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE:PSH), a clinical- stage regenerative medicine therapeutics company, today provided a corporate update and outlook for 2020.

Dr. Philip Toleikis, President and CEO of Sernova Corp., remarked, "The past year has been one of significant advancement and success for Sernova's clinical and preclinical programs. We are pleased with the progress, including increased patient enrollment and early observations from our US Phase I/II clinical trial for people with type 1 diabetes and severe hypoglycemia unawareness. Advancements have also been made with preclinical initiatives for our Cell Pouch System™ platform relating to the development of stem cell-derived islets toward the ultimate goal of developing an unlimited source of therapeutic cells for diabetes, factor VIII producing cells for hemophilia A and a novel treatment for people with hypothyroid disease. We also continue to evolve and make progress with our pharma and academic collaborations. Despite the current COVID-19 environment, we are encouraged with the path ahead for Sernova and what we expect to achieve in 2020 to enhance long-term shareholder value."

The following enumerates recent progress and achievements for Sernova's pipeline by therapeutic indication and area of interest.

Diabetes

We are currently conducting a US Phase I/II clinical trial in type 1 diabetic patients with severe hypoglycemia unawareness – entitled "Safety, Tolerability and Efficacy Study of Sernova's Cell Pouch™ for Clinical Islet Transplantation" - at the University of Chicago ("US Phase I/II Cell Pouch Clinical Trial").

Key requirements for a successful diabetes regenerative medicine approach have been our focus, more specifically, these include first ensuring robust survival of insulin-producing cells within our Cell Pouch and proof of insulin release into the bloodstream in subjects with no ability to produce insulin prior to Cell Pouch transplant.

The following represents significant achievements for the US Phase I/II Cell Pouch Clinical Trial:

• Increased number of patients enrolled and transplanted in our clinical trial. In the most advanced patient treated with the Cell Pouch and insulin-producing islets, abundant and surviving vascularized insulin-producing islets were confirmed in the sentinel Cell Pouch by independent pathologist assessment following 90 days transplant.

 Why is this important? This early efficacy endpoint within the sentinel Cell Pouch is an indicator of transplanted islet health in the therapeutic Cell Pouches remaining in the patient, including the islets ability to read blood sugar and produce insulin into the bloodstream.

• Enduring bloodstream levels of insulin from the Cell Pouch transplanted islet cells in the fasting patient was shown through detection of C-peptide, a biomarker of insulin produced by the islet cells.

 Why is this important? This finding, combined with glucose-stimulated C-peptide and other early efficacy indicators observed, is an indication of a normalizing response by the Cell Pouch therapeutic cells to the body's varied need for insulin production, i.e. an indicator and evidence of ongoing islet survival within the vascularized environment of the Cell Pouch.

• The independent Data Safety Monitoring Board (DSMB) completed its first review of our US Phase I/II Cell Pouch Clinical Trial. No safety concerns were raised, and continuation of the clinical study was recommended.

 Why is this important? Independent DSMB review of the trial on a yearly basis in compliance with FDA guidelines and confirmation of favorable safety profile of the Cell Pouch and islets.

Hemophilia A

• The HemAcure Consortium, a collaboration including Sernova and a team of European academic investigators that received €5.6M funding from the EU Horizon 2020 program, successfully completed its objective to research and develop a therapeutic approach that would provide constant delivery of factor VIII to normalize blood levels in an effort to significantly improve the quality of life of patients suffering from hemophilia A.

• A series of breakthroughs were achieved demonstrating success in correcting cells from the blood of patients with hemophilia A to produce the required factor VIII protein within the implanted Cell Pouch resulting in improvement in blood clotting in an animal model of hemophilia A in preparation for future completion of formal preclinical studies and potential advancement to human clinical trials. Hypothyroid Disease

• Sernova has established a collaboration with Dr. Sam Wiseman of the University of British Columbia for development of a novel Cell Pouch Cell Therapy approach with the goal to reverse the serious effects of hypothyroidism, which occurs following removal of the thyroid gland in over 150,000 patients each year in the US.

• This collaboration, supported by Sernova and a Transplant Research Foundation (TRF) of British Columbia Transplant Venture grant award, has made important advancements, and study results are anticipated for release in 2020.

Local Immune Protection Technologies

• Local immune protection of therapeutic cells within the Cell Pouch would represent a major advance in cell therapy as it would reduce or eliminate the need for immunosuppression drugs and reduce both the potential of side effects and risk profile for cell therapy patients.

• We are continuing to evaluate local immune protection approaches with the objective of providing locally immune protected therapeutic cells within our Cell Pouch to improve current cell therapy treatment options.

Collaborations

• Sernova's current collaborations with leading pharma, medtech, and academic researchers are progressing according to plan. We continue to field collaboration inquiries from other international and large regional pharma companies.

• Current collaborations include the assessment of safety and efficacy of combined technologies in preclinical studies, which could lead to strategic development or commercial partnership opportunities for diabetes and our other platform technologies.

2020 Outlook

Some of our key initiatives for 2020 include:

• Focusing on patient enrollment completion which includes Cell Pouch implantation and the continued advancement of our US Phase I/II Cell Pouch Clinical Trial;

• Evolving stem cell-derived islet technologies, with the end goal to provide an unlimited supply of stem cell-derived islet cells for the anticipated treatment of any person inflicted with insulin-dependent diabetes;

• Continuing the evaluation of alternative novel local immune protection technologies for therapeutic cells, to be used in conjunction with our Cell Pouch technologies, for potential in-licensing or acquisition;

• Advancing further IND enabling preclinical proof of concept studies for the treatment of postoperative hypothyroid disease;

• Developing additional collaborations with pharma companies; and

• Releasing results of our research through publications in peer-reviewed scientific journals and conferences.

"While COVID-19 has introduced uncertainties for all people and businesses worldwide, we are proactively evolving how we operate and are adopting alternative methods and approaches to enable us to carry on our business and the US Phase I/II Cell Pouch Clinical Trial with the goal of mitigating potential impact. We are also continuing to advance our scientific, clinical and business activities within the context of the COVID-19 situation and are committed to following the evolving guidelines recommended by WHO, CDC, and the Federal and Provincial Governments of Canada to protect the safety of our employees and families, collaborators and business partners," said Dr. Philip Toleikis. He continued, "Despite the current environment, we are focused and committed to build upon our recent clinical and preclinical program achievements towards further important advancements in 2020 to deliver long-term value to our shareholders."

ABOUT SERNOVA'S CLINICAL TRIAL

Sernova is conducting a Phase I/II non-randomized, unblinded, single-arm, company-sponsored trial to assess the safety and tolerability of islet transplantation into the company's patented Cell Pouch in participants with diabetes and hypoglycemia unawareness. The secondary objective is to assess efficacy through a series of defined measures. Importantly, patients enrolled in Sernova's clinical trial are incapable of producing C- peptide, a marker of insulin produced by islet cells prior to implantation of Sernova's Cell Pouch and therapeutic cells.

Eligible subjects are implanted with Cell Pouches. Following the development of vascularized tissue chambers within the Cell Pouch, subjects are then stabilized on immunosuppression and a dose of purified islets, under strict release criteria, transplanted into the Cell Pouch.

A sentinel pouch is removed for an early assessment of the islet transplant. Subjects are followed for additional safety and efficacy measures for approximately six months. At this point, a decision is made with regards to the transplant of a second islet dose with subsequent safety and efficacy follow up. Patients are then further followed for one year to assess longer term safety and efficacy.

For more information on this clinical trial, please visit www.clinicaltrials.gov/ct2/show/NCT03513939. For more information on enrollment and recruitment details, please visit www.pwitkowski.org/sernova.

ABOUT SERNOVA'S CELL POUCH SYSTEM

The Cell Pouch as part of the Cell Pouch System is a novel, proprietary, scalable, implantable macro- encapsulation device solution designed for the long-term survival and function of therapeutic cells. The device upon implantation is designed to incorporate with tissue, forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells which then release proteins and hormones as required to treat disease. The Cell Pouch along with therapeutic cells has been shown to provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for insulin-producing cells in humans.

ABOUT SERNOVA CORP.

Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells, i.e. human donor cells, corrected human cells and stem cell derived cells, to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin- dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com

FOR FURTHER INFORMATION, PLEASE CONTACT:

Dominic Gray Sernova Corp Tel: (519) 858-5126 dominic.gray@sernova.com www.sernova.com

FORWARD-LOOKING INFORMATION

This release contains statements that, to the extent they are not recitations of historical facts, may constitute "forward-looking statements" that involve various risks, uncertainties and assumptions, including, without limitation, statements regarding the future prospects, plans and objectives of the company. Wherever possible, but not always, words such as "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential for" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur are used to identify forward-looking statements. These statements reflect management's beliefs with respect to future events and are based on information currently available to management on the date such statements were made. Many factors could cause Sernova's actual results, performances or achievements to not be as anticipated, estimated or intended or to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors could include, but are not limited to, the company's ability to secure additional financing and licensing arrangements on reasonable terms, or at all; ability to conduct all required preclinical and clinical studies for the company's Cell Pouch System and/or related technologies, including the timing and results of those trials; ability to obtain all necessary regulatory approvals, or on a timely basis; ability to in-license additional complementary technologies; ability to execute its business strategy and successfully compete in the market; and the inherent risks associated with development of biotechnology combination products generally. Many of the factors are beyond our control, including those caused by, related to or impacted by the novel coronavirus pandemic. Investors should consult the company's quarterly and annual filings available on www.sedar.com for additional information on risks and uncertainties relating to the forward-looking statements. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Press Release Communiqué de presse - February 17, 2020 17 February, 2020

Sernova to Present Corporate Update at Noble Capital Markets Investor Conference

February 17, 2020 9:00 a.m. EDT

LONDON, ONTARIO – February 17, 2020 – Sernova Corp (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical- stage regenerative medicine therapeutics leader announced today that President and CEO Dr. Philip Toleikis will present at NobleCon16 on February 18th at 2:00 p.m. NobleCon16 is Noble Capital Markets' 16th Annual Investor Conference featuring emerging growth companies being held at the Seminole Hard Rock Hotel & Casino, Hollywood, Florida from February 17-18th, 2020.

A high-definition, video webcast of the presentation will be available the following day on Sernova’s website www.sernova.com and available at www.nobleconference.com and on Channelchek, Noble’s investor portal www.channelchek.com.

ABOUT SERNOVA’S CLINICAL TRIAL

Sernova is conducting a Phase I/II non-randomized, unblinded, single-arm, company-sponsored trial to assess the safety and tolerability of islet transplantation into the company’s patented Cell Pouch in diabetic subjects with hypoglycemia unawareness. The secondary objective is to assess efficacy through a series of defined measures. Patients enrolled in Sernova’s clinical trial are incapable of producing C-peptide, a biomarker for insulin produced by islet cells.

Eligible subjects are implanted with Cell Pouches. Following the development of vascularized tissue chambers within the Cell Pouch, subjects are then stabilized on immunosuppression and a dose of purified islets, under strict release criteria, transplanted into the Cell Pouch.

A sentinel pouch is removed for an early assessment of the islet transplant. Subjects are followed for additional safety and efficacy measures for approximately six months. At this point, a decision is made with regards to the transplant of a second islet dose with subsequent safety and efficacy follow up. Patients will be then further followed for one year to assess longer-term safety and efficacy.

For more information on the clinical trial A Safety, Tolerability and Efficacy Study of Sernova's Cell Pouch™ for Clinical Islet Transplantation, please visit www.clinicaltrials.gov/ct2/show/NCT03513939. For more information on enrollment and recruitment details please visit www.pwitkowski.org/sernova.

ABOUT SERNOVA CORP Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells (i.e. human donor cells, corrected human cells and stem cell-derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com

For further information contact: Dominic Gray Sernova Corp Tel: (519) 858-5126 dominic.gray@sernova.com www.sernova.com

FORWARD-LOOKING INFORMATION This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of Sernova’s management on the date such statements were made, which include our beliefs about the conduct and outcome of clinical trials. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Press Release Communiqué de presse - February 13, 2020 13 February, 2020

Sernova Achieves Positive Efficacy Endpoint in Phase I/II Clinical Trial for Type 1 Diabetes

Most advanced subject in the clinical trial continues to show positive indicators of islet function following islet transplant into the Cell Pouch

February 13, 2020 9:00 a.m. EDT

LONDON, ONTARIO – February 13, 2020 – Sernova Corp (TSX-V:SVA)(OTCQB:SEOVF)(FSE:PSH), a clinical- stage company and regenerative medicine therapeutics leader, is pleased to announce that Sernova’s first treated patient in its Phase I/II clinical trial of its Cell Pouch with therapeutic cells for type 1 diabetes at the University of Chicago, has demonstrated survival of endocrine tissue (insulin-producing islets) in the sentinel Cell Pouch following 90 days transplant.

This efficacy outcome, namely, survival of endocrine tissue (insulin-producing islets) in the sentinel Cell Pouch following 90 days transplant, is measured by positive staining of islets during histological analysis. According to the independent pathologist who conducted the analysis, “The explanted sentinel pouch shows abundant viable, organized islet cells intimately associated with blood vessels within a collagen matrix after 90 days of transplantation. These surviving islet cells strongly express insulin.” A representative histological image from the islet-transplanted mini-sentinel Cell Pouch explanted from a patient at 90 days post-transplant. Islets with positive insulin staining (red), and new blood vessels (green) are detected. (A Safety, Tolerability and Efficacy Study of Sernova's Cell Pouch™ for Clinical Islet Transplantation.)

This achievement is important because it is an indicator of transplanted islet health in the therapeutic Cell Pouches remaining in the subject, including the islets ability to produce insulin into the bloodstream. This has been demonstrated by our previous reported findings of blood levels of both glucose-stimulated and fasting C- peptide as well as other efficacy indicators in this patient who had no measurable levels of this biomarker of insulin prior to the Cell Pouch islet transplant.

“We believe these accumulating positive results continue to validate our Cell Pouch technologies as a viable regenerative medicine therapeutic platform for humans in insulin-dependent diabetes and other chronic diseases,” said Dr. Philip Toleikis, President and CEO of Sernova Corp. “With these encouraging results and the positive review and recommendation from the Data Safety and Monitoring Board (DSMB), we are excited to continue the clinical trial and carry on compiling safety and efficacy data from our current and future treated patients.”

ABOUT SERNOVA’S CLINICAL TRIAL

Sernova is conducting a Phase I/II non-randomized, unblinded, single-arm, Company-sponsored trial to assess the safety and tolerability of islet transplantation into the company’s patented Cell Pouch in diabetic subjects with hypoglycemia unawareness. The primary objective of the study is to assess the safety of the Cell Pouch following implantation and transplantation. The secondary objective is to assess efficacy through a series of defined measures. Patients enrolled in Sernova’s clinical trial are incapable of producing C-peptide, a biomarker for insulin produced by islet cells.

Eligible subjects are implanted with Cell Pouches. Following the development of vascularized tissue chambers within the Cell Pouch, subjects are then stabilized on immunosuppression and a dose of purified islets, under strict release criteria, is transplanted into the Cell Pouch.

A sentinel pouch is removed for an early assessment of the islet transplant. Subjects are followed for additional safety and efficacy measures for approximately six months. At this point, a decision will be made with regards to the transplant of a second islet dose with subsequent safety and efficacy follow up. Patients will be then further followed for one year to assess longer-term safety and efficacy.

For more information on the clinical trial, please visit www.clinicaltrials.gov/ct2/show/NCT03513939. For more information on enrollment and recruitment details please visit www.pwitkowski.org/sernova.

ABOUT SERNOVA’S CELL POUCH SYSTEM

The Cell Pouch System including the Cell Pouch, which is a novel, proprietary, scalable, implantable macro- encapsulation device solution designed for the long- term survival and function of therapeutic cells. The device upon implantation is designed to incorporate with tissue, forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells which then release proteins and hormones as required to treat disease. The Cell Pouch along with therapeutic cells has been shown to provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for insulin-producing cells in humans. In early assessments of its ongoing Phase I/II clinical trial, Sernova has shown in its first treated patient presence of blood levels of C-peptide both during glucose tolerance tests as well as under fasting conditions. Clinical testing is ongoing at the University of Chicago.

ABOUT SERNOVA CORP

Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells (i.e. human donor cells, corrected human cells and stem cell-derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin- dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com

For further information contact: Dominic Gray Sernova Corp Tel: (519) 858-5126 dominic.gray@sernova.com www.sernova.com

FORWARD-LOOKING INFORMATION

This press release contains forward-looking statements within the meaning of applicable Canadian securities laws. Forward-looking statements in this press release are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Forward-looking statements include statements about subsequent clinical activity, including enrolment of patients and continuing results therefrom, and the potential benefits, safety, and efficacy of the Cell Pouch for various indications, including type 1 diabetes.

While Sernova considers these assumptions to be reasonable, these assumptions are inherently subject to significant scientific, business, economic, competitive, market and social uncertainties and contingencies. Additionally, there are known and unknown risk factors that could cause Sernova’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements contained in this press release. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. Readers should not place undue reliance on these statements or the scientific data presented and should refer to the risk factors identified in the company’s continuous disclosure filed on SEDAR. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Privacy PolicyPolitique de confidentialité